The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis

BackgroundBoth sodium-glucose co-transporter-2 (SGLT-2) inhibitors and angiotensin receptor-neprilysin inhibitor (ARNI) were recommended to treat heart failure with reduced ejection fraction (HFrEF). However, no trial was conducted to assess the efficacy and safety of the combined therapy of SGLT-2...

Full description

Bibliographic Details
Main Authors: Yanxia Lin, Huanrui Zhang, Shijie Zhao, Ling Chen, Jinyang Li, Xiaoou Wang, Wen Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
sodium-glucose co-transporter-2 inhibitors
angiotensin receptor-neprilysin inhibitor
combined therapy
heart failure
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.882089/full

Similar Items

Similar Items